Christopher R. Bethel

Christopher R. Bethel

Auto-generated profile, based on publicly available information

Christopher R. Bethel

Research Service Louis Stokes Cleveland Department of Veterans Affairs Cleveland OH USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2025 in Chemical Science
Verified
Journal Article
Open access
PDF file
BWBrenda Agustina Warecki
Brenda Agustina Warecki
PTPablo Emiliano Tomatis
Pablo Emiliano Tomatis
MMMaria Mojica
Maria Mojica
CBChristopher R. Bethel
Christopher R. Bethel
MSMagdalena Rodríguez Saravia
Magdalena Rodríguez Saravia
AVAlejandro Vila
Alejandro Vila
The metallo-β-lactamase NDM is able to inactivate the last-generation antibiotic cefiderocol (FDC), in contrast to the related enzymes VIM and IMP. These results provide clues for the therapeutic use of FDC.

13 September 2025 in FEBS Letters
Verified
Journal Article
Open access
MBMichael Beer
Michael Beer
PHPhilip Hinchliffe
Philip Hinchliffe
MHMarko Hanževački
Marko Hanževački
CBChristopher R. Bethel
Christopher R. Bethel
CTCatherine L. Tooke
Catherine L. Tooke
JSJames Spencer
James Spencer
β‐Lactamase‐catalysed hydrolysis is the primary form of β‐lactam antibiotic resistance in Gram‐negative bacteria. The penicillanic acid sulfone (PAS) enmetazobactam is thought to inhibit extended‐spectrum β‐lactamases (ESBLs) by fragmentation of an initial acyl‐enzyme to form an active‐site lysinoalanine cross link. We investigate interactions of enmetazobactam and its congener tazobactam with GES‐1, an ESBL with structural features of carbapenem‐hydrolysing β‐lactamases. Crystal structures show different breakdown products of the two inhibitors covalently bound to the catalytic Ser70, assigned using quantum mechanics/molecular mechanics (QM/MM) calculations. We find no evidence for lysinoalanine formation, with mass spectrometry indicating active enzyme regeneration, behaviour previously observed for carbapenem‐hydrolysing enzymes, but not ESBLs. This work establishes that PAS inhibitors interact with diverse β‐lactamases by differing mechanisms, which should inform development of future compounds.